Jetrea(ocriplasmin)
Jetrea (ocriplasmin) is a protein pharmaceutical. Ocriplasmin was first approved as Jetrea on 2012-10-17. It is used to treat retinal diseases in the USA. It has been approved in Europe to treat retinal diseases.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| retinal diseases | — | D012164 | H35.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J7316 | Injection, ocriplasmin, 0.125 mg |
Clinical
Clinical Trials
523 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tissue adhesions | D000267 | — | — | — | 3 | 3 | — | 3 | 9 |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vitrectomy | D014821 | — | — | — | 3 | — | — | — | 3 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 3 | — | — | — | 3 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | 2 | — | — | — | 2 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | — | 2 | — | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | — | — | — | 2 |
| Retinal diseases | D012164 | — | H35.9 | — | 1 | — | — | — | 1 |
| Disease progression | D018450 | — | — | — | 1 | — | — | — | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 1 | — | — | — | 1 |
| Vitreous detachment | D020255 | EFO_1001238 | H43.81 | — | 1 | — | — | — | 1 |
| Thrombosis | D013927 | — | — | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ocriplasmin |
| INN | ocriplasmin |
| Description | Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.
|
| Classification | Enzyme |
| Drug class | plasmin proteins and derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2095222 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08888 |
| UNII ID | 7V6HE3DM5A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 681 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
691 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use